Everything below concerns Peptidomimetic. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-10. Numbers and descriptions here follow the published literature rather than marketing material.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
M-phase inducer phosphatase: CDC25A; CDC25B; CDC25C; Dual specificity protein phosphatase: DUSP; DUSP1; DUSP2; DUSP4; DUSP5; DUSP6; DUSP7; DUSP10; DUSP16, aka MKP7; Thiosulfate:glutathione sulfurtransferase: KAT, now known as "TSTD1"; Adenylyltransferase and sulfurtransferase: MOCS3; 3-mercaptopyruvate sulfurtransferase: MPST, also known as "TSTD2" Not an enzyme: TBCK; TSGA14; Ubiquitin carboxyl-terminal hydrolase: USP8; Unknown activity: TSTD3
==== Cognitive performance ==== In 2015, a systematic review and a meta-analysis of high quality clinical trials found that, when used at low (therapeutic) doses, amphetamine produces modest yet unambiguous improvements in cognition, including working memory, long-term episodic memory, inhibitory control, and some aspects of attention, in normal healthy adults; these cognition-enhancing effects of amphetamine are known to be partially mediated through the indirect activation of both dopamine D1 receptor and α2-adrenergic receptor in the prefrontal cortex. A systematic review from 2014 found that low doses of amphetamine also improve memory consolidation, in turn leading to improved recall of information. Therapeutic doses of amphetamine also enhance cortical network efficiency, an effect which mediates improvements in working memory in all individuals. Amphetamine and other ADHD stimulants also improve task saliency (motivation to perform a task) and increase arousal (wakefulness), in turn promoting goal-directed behavior. Stimulants such as amphetamine can improve performance on difficult and boring tasks and are used by some students as a study and test-taking aid. Based upon studies of self-reported illicit stimulant use, 5–35% of college students use diverted ADHD stimulants, which are primarily used for enhancement of academic performance rather than as recreational drugs. However, high amphetamine doses that are above the therapeutic range can interfere with working memory and other aspects of cognitive control.
. Rate of electron capture dissociation not only depends on the frequency of ion–electron fragmentation reactions but also on the number of ions in an ion–electron interaction volume. Electron current density and cross-section of ECD is directly proportional to fragmentation frequency. An indirectly heated dispenser cathode used as an electron source results in larger electron current and larger emitting surface area.
Sources: en.wikipedia.org
=== Parasitic disease === The leading cause of iron-deficiency anemia worldwide is a parasitic disease known as a helminthiasis caused by infestation with parasitic worms (helminths); specifically, hookworms. The hookworms most commonly responsible for causing iron-deficiency anemia include Ancylostoma duodenale, Ancylostoma ceylanicum, and Necator americanus. The World Health Organization estimates that approximately two billion people are infected with soil-transmitted helminths worldwide. Parasitic worms cause both inflammation and chronic blood loss by binding to a human's small-intestinal mucosa, and through their means of feeding and degradation, they can ultimately cause iron-deficiency anemia.
Mrs Justice Cheema-Grubb tells Alid: "The murder of Terence Carney was a terrorist act in which you hoped to influence the British government. You hoped to frighten the British people and undermine the freedoms they enjoy." The UK Health Security Agency confirms the number of cases of cryptosporidiosis in south Devon has risen to 46. Sir Paul McCartney has become the first billionaire British musician according to the 2024 Sunday Times Rich List. 18 May South West Water tells residents in most of Brixham, south Devon they no longer have to boil water before drinking it, but continues to advise households in upper Brixham, Hillhead and Kingswear to do so. The Met Office issues a weather warning for severe thunderstorms for Wales, south west England and the West Midlands. A number of people are reported to be isolating on the cruise ship MV Ventura with gastrointestinal symptoms. Technical problems result in customers being unable to use the M&S website and app for several hours. Declassified documents clear the Welsh Guards of any responsibility in the Argentinian Air Force bombing of RFA Sir Galahad on 8 June 1982, leading to the biggest loss of British lives during the Falklands War; some had blamed the Welsh Guards for disobeying orders to leave the ship, where 48 crewmen were killed. 19 May – South West Water apologises after 30 households in south Devon were wrongly told they could stop boiling water. 20 May The results of a public inquiry into the contaminated blood scandal are published.
Marfan syndrome (MFS) is a multisystemic genetic disorder that affects the connective tissue. People with the condition are often tall and thin, with long arms, legs, fingers, and toes. They also typically have exceptionally flexible joints and abnormally curved spines. The most serious complications involve the heart and aorta, with an increased risk of mitral valve prolapse and aortic aneurysm. The lungs, eyes, bones, and the covering of the spinal cord are also commonly affected. The severity of the symptoms is variable. MFS is caused by a mutation in FBN1, one of the genes that make fibrillin, which results in abnormal connective tissue. It is an autosomal dominant disorder. In about 75% of cases, it is inherited from a parent with the condition, while in about 25%, it is a new mutation. Diagnosis is often based on the Ghent criteria, family history, and genetic testing (DNA analysis). No cure for MFS is known. Many of those with the disorder have a normal life expectancy with proper treatment. Management often includes the use of beta blockers such as propranolol or atenolol, calcium channel blockers, ACE inhibitors, and/or angiotensin receptor blockers (ARBs). Surgery may be required to repair the aorta or replace a heart valve. Avoiding strenuous exercise is recommended for those with the condition. About one in 5,000 to 10,000 people have MFS. Rates of the condition are similar in different regions of the world. It is named after French pediatrician Antoine Marfan, who first described it in 1896.
Sources: en.wikipedia.org
== External referencing for NPU concepts == A key benefit of the NPU terminology is clear definition of terms. Codes are generally only applied where a clear external database reference is available for unequivocal definition of terms.
Acebutolol (has intrinsic sympathomimetic activity, ISA) Atenolol Betaxolol Bisoprolol Celiprolol (has intrinsic sympathomimetic activity) Metoprolol Nebivolol Esmolol Nebivolol and bisoprolol are the most β1 cardioselective beta blockers.
== Interactions == Sirolimus is metabolized by the CYP3A4 enzyme and is a substrate of the P-glycoprotein (P-gp) efflux pump; hence, inhibitors of either protein may increase sirolimus concentrations in blood plasma, whereas inducers of CYP3A4 and P-gp may decrease sirolimus concentrations in blood plasma.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.